Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review
- Authors: Zhirov I.V.1,2, Safronova N.V.1, Tereshchenko S.N.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 95, No 9 (2023)
- Pages: 802-809
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/254697
- DOI: https://doi.org/10.26442/00403660.2023.09.202400
- ID: 254697
Cite item
Full Text
Abstract
Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden. This review describes recent studies on the use of sacubitril/valsartan in heart failure patients with mildly reduced or preserved ejection fraction.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Zhirov
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4066-2661
Medicorum Scientiarum Doctor, Investigator Princeps Department of Morborum Myocardialium et Cordis Defectus, Professor Department of Cardiologiae
Russian Federation, Moscow; MoscowNatalia V. Safronova
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0001-6624-3804
Candidatus Scientiarum Medical, Junior Investigator, Department of Myocardial Morborum et Cordis Defectus
Russian Federation, MoscowSergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0001-9234-6129
Doctor of Medical Sciences, Professor, Head of Department myocardial diseases and heart failure
Russian Federation, MoscowReferences
- Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87. doi: 10.1093/cvr/cvac013
- Хроническая сердечная недостаточность, клинические рекомендации Минздрава России, 2020 г. Режим доступа: https://cr.minzdrav.gov.ru/recomend/156_1. Ссылка активна на 07.09.2023 [Chronic heart failure, clinical recommendations of the Russian Ministry of Health, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1. Accessed: 07.09.2023 (in Russian)].
- McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032. doi: 10.1161/CIR.0000000000001063
- Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol. 2022;45 Suppl. 1(Suppl. 1):S31-39. doi: 10.1002/clc.23846
- Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-16. doi: 10.1038/s41569-021-00605-5
- Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. doi: 10.1002/ejhf.813
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7
- Joseph P, Dokainish H, McCready T, et al; G-CHF Investigators. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. Am Heart J. 2020;227:56-63. doi: 10.1016/j.ahj.2020.06.002
- Zhirov I, Safronova N, Osmolovskaya Y, et al. Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. Cardiol Res Pract. 2019;2019:1692104. doi: 10.1155/2019/1692104
- Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476-86. doi: 10.1016/j.jacc.2017.08.074
- Shiga T, Suzuki A, Haruta S, et al; HIJ-HF II Investigators. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail. 2019;6(3):475-86. doi: 10.1002/ehf2.12418
- Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996-1004. doi: 10.1001/jamainternmed.2015.0924
- Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018;6(8):678-85. doi: 10.1016/j.jchf.2018.03.006
- Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2
- Solomon SD, Vaduganathan M, Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352-61. doi: 10.1161/CIRCULATIONAHA.119.044586
- Chioncel O, Mebazaa A, Harjola VP, et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-54. doi: 10.1002/ejhf.890
- Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-25. doi: 10.1002/ejhf.566
- Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Сердечная недостаточность. 2014;15(2):67-75 [Arutyunov AG, Rylova AK, Arutyunov GP. Registry of hospitalized patients with decompensated circulation ("Pavlov’s hospital registr"). Report 2. Clinical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with decompensated circulation. Heart Failure Journal. 2014;15(2):67-75 (in Russian)]. doi: 10.18087/rhfj. 2014.2.1934
- Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-7. doi: 10.1161/CIRCULATIONAHA.107.696906
- Solomon SD, Zile M, Pieske B, et al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6
- Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-20. doi: 10.1056/NEJMoa1908655
- Vaduganathan M, Claggett BL, Desai AS, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245-54. doi: 10.1016/j.jacc.2019.11.003
- Kristensen SL, Jhund PS, Køber L, et al. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015;3(6):478-86. doi: 10.1016/j.jchf.2015.01.014
- Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020;8(5):372-81. doi: 10.1016/j.jchf.2020.03.002
- Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019;73(11):1264-72. doi: 10.1016/j.jacc.2019.01.018
- Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. doi: 10.1056/NEJMoa1812851
- Mentz RJ, Ward JH, Hernandez AF, et al. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. J Card Fail. 2023;29(6):922-30. doi: 10.1016/j.cardfail.2023.02.001
- Mentz RJ, Ward JH, Hernandez AF, et al; PARAGLIDE-HF Investigators. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. doi: 10.1016/j.jacc.2023.04.019
- Fudim M, Khan MS, Paracha AA, et al. Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond. Circ Heart Fail. 2022;15(3):e009340. doi: 10.1161/CIRCHEARTFAILURE.121.009340
- Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023:ehad344. doi: 10.1093/eurheartj/ehad344